Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacytidine and DLI for Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
NCT02017457Phase 2Completed
- Start
- Dec 2013
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS). Started Dec 2013; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02017457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017457.